Journals / Tüberküloz ve Toraks / 2021 / Cilt: 69 - Sayı: 2

In vitro activity of methylene blue on Mycobacterium tuberculosis complex isolates

Metilen mavisinin Mycobacterium tuberculosis kompleks izolatlarına in vitro etkisi

Pages
279–284
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We conclude that methylene blue may become a potential anti-tuberculosis agent due to its well-known side effects and dosing regimens.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Methylene blue is used for bacterial staining in microbiology and as an antidote drug in medicine.
📊
Key Findings & Data:Mycobacteria Growth Indicator tubes containing methylene blue at critical concentrations of 0.2, 2, 20, 1000 µg ml-1 and control tube were prepared.
💡
Conclusion & Impact:We conclude that methylene blue may become a potential anti-tuberculosis agent due to its well-known side effects and dosing regimens.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Methylene blue is used for bacterial staining in microbiology and as an antidote drug in medicine. In this study, we aimed to investigate the antimicrobial effects of methylene blue against Mycobacterium tuberculosis complex clinical isolates. Seventeen stored M. tuberculosis complex clinical isolates were included in the study. The isolates were inoculated into Mycobacteria Growth Indicator Tubes and incubated in Automated Mycobacterial Detection System. Mycobacteria Growth Indicator tubes containing methylene blue at critical concentrations of 0.2, 2, 20, 1000 µg ml-1 and control tube were prepared. Antimicrobial susceptibility testing was performed using Automated Mycobacterial Detection System which is gold standard for second line anti-tuberculosis drug testing. At the end of the study, six clinical isolates were susceptible to methylene blue at all critical concentrations. Five isolates were susceptible to only 1000 µg ml-1 methylene blue. Three isolates were susceptible to 1000 and 20 µg ml-1 methylene blue. Susceptibility rate was found as 94% when the critical proportion was accepted 400 GU (1/100 of control). Significant relationship was observed between the administered methylene blue concentrations and bacterial survival rate in statistical analysis. We conclude that methylene blue may become a potential anti-tuberculosis agent due to its well-known side effects and dosing regimens.

Özet

Metilen mavisi mikrobiyolojide bakteri boyası ve tıpta antidot ilaç olarak kullanmaktadır. Bu çalışmada, metilen mavisinin Mycobacterium tuberculosis kompleks klinik izolatlarına karşı antimikrobiyal etkilerinin araştırılması amaçlanmıştır. Önceden saklamaya alınmış 17 Mycobacterium tuberculosis kompleks klinik izolatı çalışmaya alındı. İzolatlar Mycobacteria Growth Indicator Tubes (MGIT) besiyerlerine inoküle edildi ve akabinde Otomatize Mikobakteri Tanımlama Sistemi (OMTS)’nde enkübasyona kaldırıldı. Her izolat için 0.2, 2, 20 ve 1000 µg ml-1 kritik konsantrasyonlarında metilen mavisi içeren MGIT tüpleri ve kontrol tüpü hazırlandı. Antibiyogramlar, ikinci seçenek anti-tüberküloz ilaç duyarlılık testleri için altın standart kabul edilen OMTS kullanılarak yapıldı. Çalışma sonunda, altı klinik izolat tüm kritik konsantrasyonlarda metilen mavisine duyarlı bulundu. Beş izolat ise sadece 1000 µg ml-1 konsantrasyonda metilen mavisine duyarlı olarak tespit edildi. Üç izolat 1000 ve 20 µg ml-1 kritik konsantrasyonda metilen mavisine duyarlı bulundu. Kritik proporsiyon 400 GU (kontrolün 1/100’ü) kabul edildiğinde metilen mavisine duyarlılık oranı %94 olarak hesaplandı. İstatistiki analizde, uygulanan metilen mavisi konsantrasyonları ile bakteriyel sağkalım oranı arasında anlamlı bir ilişki gözlemlendi. Metilen mavisi, bilinen yan etkileri ve var olan doz rejim protokolleri nedeniyle, potansiyel bir anti-tüberküloz ajan olabilir

🔖

Cite This Article

GAZEL, D., GAZEL, Ö. Z. (2022). In vitro activity of methylene blue on Mycobacterium tuberculosis complex isolates. Tüberküloz ve Toraks, Cilt: 69 - Sayı: 2, 279–284. https://ajindex.com/articles/618298

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007; 51(4): 1534-6
  2. Tato M, de la Pedrosa EG, Canton R, Gomez-Garcia I, Fortun J, Martin-Davila P, et al. In vitro activity of linezolid against Mycobacterium tuberculosis complex, including multidrug-resistant Mycobacterium bovis isolates. Int J Antimicrob Agents 2006; 28(1): 75-8
  3. Misclescu A, Wiklund L. Methylene blue, an old drug with new indications? Rom J Anaesth Intensive Care 2010; 17(1): 35-41
  4. Barrett NM, Alston TA. Literature reviews: Methylene blue added to a hypertonic-hyperoncotic solution increases shorttime survival in experimental cardiac arrest. ASA Newsletter 2006; 5: 7-8
  5. Siddiqi SH, Rüsch-Gerdes S. MGIT Procedure Manual. Foundation for Innovative Diagnostics; 2006. 89 pages. Available from: https://www.finddx.org/wp-content/ uploads/2016/02/mgit_manual_nov2006.pdf (Accessed date: 3 October 2020)
  6. World Health Organization (WHO). Framework for implementing new tuberculosis diagnostics. Geneva, Switzerland: World Health Organization; 2010. 24 p. Available from: https://www.who.int/tb/laboratory/ whopolicyframework_july10_revnov10.pdf (Accessed date: 3 November 2020)
  7. Pal R, Ansari MA, Saibabu V, Das S, Fatima Z, Hameed S. Nonphotodynamic roles of methylene blue: display of distinct antimycobacterial and anticandidal mode of actions. J Pathog 2018; 3759704. Available from: https:// www.hindawi.com/journals/jpath/2018/3759704/ (Accessed date: 3 November 2020)
  8. Walter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O, Meissner P, et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol 2009;65(2):179-89
  9. Peter C, Hongwan D, Küpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000; 56(3): 247-50
  10. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, et al. Mycobacteria: Laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 1963; 29: 565-78
  11. Fadel M, Salah M, Samy N, Mona S. Liposomal methylene blue hydrogel for selective photodynamic therapy of acne vulgaris. J Drugs Dermatol 2009; 8(11): 983-90.